GuruFocus - On August 23, 2024, Robert Wilson, Director at CalciMedica Inc (NASDAQ:CALC), purchased 54,000 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 364,196 shares of CalciMedica Inc.
CalciMedica Inc is focused on the development of drugs to treat severe inflammatory diseases. The company's strategic approach targets the calcium release-activated calcium (CRAC) channel, a crucial component in the activation of immune cells.
The transaction occurred when shares of CalciMedica Inc were priced at $3.72, resulting in a total investment by the insider of $200,880. This purchase reflects a continued pattern of insider acquisitions at the company, with a total of 18 insider buys over the past year and no insider sales during the same period.
Following this transaction, the market cap of CalciMedica Inc stands at approximately $44.398 million. The company's valuation metrics, including the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are accessible for further details.
Over the past year, Robert Wilson has increased his holdings by purchasing a total of 114,227 shares, indicating a strong belief in the company's future prospects. This pattern of insider buying is often seen as a positive signal by market analysts.
For more detailed information on the valuation of CalciMedica Inc, interested parties can refer to the GF Value of the stock.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This content was originally published on Gurufocus.com
